Terms: = Leukemia AND MAP2K2, MEK2, 5605, ENSG00000126934, P36507, MKK2, MAPKK2, PRKMK2
26 results:
1. DNA Copy Number Alterations and Copy Neutral Loss of Heterozygosity in Adult Ph-Negative Acute B-Lymphoblastic leukemia: Focus on the Genes Involved.
Risinskaya N; Gladysheva M; Abdulpatakhov A; Chabaeva Y; Surimova V; Aleshina O; Yushkova A; Dubova O; Kapranov N; Galtseva I; Kulikov S; Obukhova T; Sudarikov A; Parovichnikova E
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139431
[TBL] [Abstract] [Full Text] [Related]
2. Single-cell RNA sequencing distinctly characterizes the wide heterogeneity in pediatric mixed phenotype acute leukemia.
Mumme HL; Raikar SS; Bhasin SS; Thomas BE; Lawrence T; Weinzierl EP; Pang Y; DeRyckere D; Gawad C; Wechsler DS; Porter CC; Castellino SM; Graham DK; Bhasin M
Genome Med; 2023 Oct; 15(1):83. PubMed ID: 37845689
[TBL] [Abstract] [Full Text] [Related]
3. CLDN4 promotes growth of acute myeloid leukemia cells via regulating AKT and ERK1/2 signaling.
Hao S; Yang C; Song P; Shi H; Zou Y; Chen M; Wu X; Yin Y; Yu Z; Zhu W; Li M
Biochem Biophys Res Commun; 2022 Sep; 619():137-143. PubMed ID: 35760010
[TBL] [Abstract] [Full Text] [Related]
4. Fine-tuning of MEK signaling is pivotal for limiting B and T cell activation.
Houde N; Beuret L; Bonaud A; Fortier-Beaulieu SP; Truchon-Landry K; Aoidi R; Pic É; Alouche N; Rondeau V; Schlecht-Louf G; Balabanian K; Espéli M; Charron J
Cell Rep; 2022 Jan; 38(2):110223. PubMed ID: 35021072
[TBL] [Abstract] [Full Text] [Related]
5. Genetic basis for iMCD-TAFRO.
Yoshimi A; Trippett TM; Zhang N; Chen X; Penson AV; Arcila ME; Pichardo J; Baik J; Sigler A; Harada H; Fajgenbaum DC; Dogan A; Abdel-Wahab O; Xiao W
Oncogene; 2020 Apr; 39(15):3218-3225. PubMed ID: 32051554
[TBL] [Abstract] [Full Text] [Related]
6. Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms.
Durham BH; Lopez Rodrigo E; Picarsic J; Abramson D; Rotemberg V; De Munck S; Pannecoucke E; Lu SX; Pastore A; Yoshimi A; Mandelker D; Ceyhan-Birsoy O; Ulaner GA; Walsh M; Yabe M; Petrova-Drus K; Arcila ME; Ladanyi M; Solit DB; Berger MF; Hyman DM; Lacouture ME; Erickson C; Saganty R; Ki M; Dunkel IJ; Santa-María López V; Mora J; Haroche J; Emile JF; Decaux O; Geissmann F; Savvides SN; Drilon A; Diamond EL; Abdel-Wahab O
Nat Med; 2019 Dec; 25(12):1839-1842. PubMed ID: 31768065
[TBL] [Abstract] [Full Text] [Related]
7. Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis.
Janku F; Diamond EL; Goodman AM; Raghavan VK; Barnes TG; Kato S; Abdel-Wahab O; Durham BH; Meric-Bernstam F; Kurzrock R
Mol Cancer Ther; 2019 Jun; 18(6):1149-1157. PubMed ID: 31015311
[TBL] [Abstract] [Full Text] [Related]
8. Expression differences of genes in the PI3K/AKT, WNT/b-catenin, SHH, NOTCH and MAPK signaling pathways in CD34+ hematopoietic cells obtained from chronic phase patients with chronic myeloid leukemia and from healthy controls.
de Cássia Viu Carrara R; Fontes AM; Abraham KJ; Orellana MD; Haddad SK; Palma PVB; Panepucci RA; Zago MA; Covas DT
Clin Transl Oncol; 2018 Apr; 20(4):542-549. PubMed ID: 28905209
[TBL] [Abstract] [Full Text] [Related]
9. Trifluoromethyl arylamides with antileukemia effect and intracellular inhibitory activity over serine/arginine-rich protein kinases (SRPKs).
Siqueira RP; Barros MVA; Barbosa ÉAA; Onofre TS; Gonçalves VHS; Pereira HS; Silva Júnior A; de Oliveira LL; Almeida MR; Fietto JLR; Teixeira RR; Bressan GC
Eur J Med Chem; 2017 Jul; 134():97-109. PubMed ID: 28407594
[TBL] [Abstract] [Full Text] [Related]
10. MEK1 is required for the development of NRAS-driven leukemia.
Nowacka JD; Baumgartner C; Pelorosso C; Roth M; Zuber J; Baccarini M
Oncotarget; 2016 Dec; 7(49):80113-80130. PubMed ID: 27741509
[TBL] [Abstract] [Full Text] [Related]
11. Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies.
Borthakur G; Popplewell L; Boyiadzis M; Foran J; Platzbecker U; Vey N; Walter RB; Olin R; Raza A; Giagounidis A; Al-Kali A; Jabbour E; Kadia T; Garcia-Manero G; Bauman JW; Wu Y; Liu Y; Schramek D; Cox DS; Wissel P; Kantarjian H
Cancer; 2016 Jun; 122(12):1871-9. PubMed ID: 26990290
[TBL] [Abstract] [Full Text] [Related]
12. Acute lymphoblastic leukemia in the context of RASopathies.
Cavé H; Caye A; Strullu M; Aladjidi N; Vignal C; Ferster A; Méchinaud F; Domenech C; Pierri F; Contet A; Cacheux V; Irving J; Kratz C; Clavel J; Verloes A
Eur J Med Genet; 2016 Mar; 59(3):173-8. PubMed ID: 26855057
[TBL] [Abstract] [Full Text] [Related]
13. Mutation in NRAS in familial Noonan syndrome--case report and review of the literature.
Ekvall S; Wilbe M; Dahlgren J; Legius E; van Haeringen A; Westphal O; Annerén G; Bondeson ML
BMC Med Genet; 2015 Oct; 16():95. PubMed ID: 26467218
[TBL] [Abstract] [Full Text] [Related]
14. MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia.
Jones CL; Gearheart CM; Fosmire S; Delgado-Martin C; Evensen NA; Bride K; Waanders AJ; Pais F; Wang J; Bhatla T; Bitterman DS; de Rijk SR; Bourgeois W; Dandekar S; Park E; Burleson TM; Madhusoodhan PP; Teachey DT; Raetz EA; Hermiston ML; Müschen M; Loh ML; Hunger SP; Zhang J; Garabedian MJ; Porter CC; Carroll WL
Blood; 2015 Nov; 126(19):2202-12. PubMed ID: 26324703
[TBL] [Abstract] [Full Text] [Related]
15. Potential Antileukemia Effect and Structural Analyses of SRPK Inhibition by N-(2-(Piperidin-1-yl)-5-(Trifluoromethyl)Phenyl)Isonicotinamide (SRPIN340).
Siqueira RP; Barbosa Éde A; Polêto MD; Righetto GL; Seraphim TV; Salgado RL; Ferreira JG; Barros MV; de Oliveira LL; Laranjeira AB; Almeida MR; Júnior AS; Fietto JL; Kobarg J; de Oliveira EB; Teixeira RR; Borges JC; Yunes JA; Bressan GC
PLoS One; 2015; 10(8):e0134882. PubMed ID: 26244849
[TBL] [Abstract] [Full Text] [Related]
16. Copper is required for oncogenic BRAF signalling and tumorigenesis.
Brady DC; Crowe MS; Turski ML; Hobbs GA; Yao X; Chaikuad A; Knapp S; Xiao K; Campbell SL; Thiele DJ; Counter CM
Nature; 2014 May; 509(7501):492-6. PubMed ID: 24717435
[TBL] [Abstract] [Full Text] [Related]
17. Trametinib: first global approval.
Wright CJ; McCormack PL
Drugs; 2013 Jul; 73(11):1245-54. PubMed ID: 23846731
[TBL] [Abstract] [Full Text] [Related]
18. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
Ho AL; Grewal RK; Leboeuf R; Sherman EJ; Pfister DG; Deandreis D; Pentlow KS; Zanzonico PB; Haque S; Gavane S; Ghossein RA; Ricarte-Filho JC; Domínguez JM; Shen R; Tuttle RM; Larson SM; Fagin JA
N Engl J Med; 2013 Feb; 368(7):623-32. PubMed ID: 23406027
[TBL] [Abstract] [Full Text] [Related]
19. Constitutional NRAS mutations are rare among patients with Noonan syndrome or juvenile myelomonocytic leukemia.
Kraoua L; Journel H; Bonnet P; Amiel J; Pouvreau N; Baumann C; Verloes A; Cavé H
Am J Med Genet A; 2012 Oct; 158A(10):2407-11. PubMed ID: 22887781
[TBL] [Abstract] [Full Text] [Related]
20. Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212.
Jing J; Greshock J; Holbrook JD; Gilmartin A; Zhang X; McNeil E; Conway T; Moy C; Laquerre S; Bachman K; Wooster R; Degenhardt Y
Mol Cancer Ther; 2012 Mar; 11(3):720-9. PubMed ID: 22169769
[TBL] [Abstract] [Full Text] [Related]
[Next]
